---
title: "Obio Technology (Shanghai) Corp., Ltd. (688238.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688238.SH.md"
symbol: "688238.SH"
name: "Obio Technology (Shanghai) Corp., Ltd."
industry: "Life Sciences Tools and Services"
---

# Obio Technology (Shanghai) Corp., Ltd. (688238.SH)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | CN Market |
| Website | [www.obiosh.com](https://www.obiosh.com) |

## Company Profile

Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoter...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:10.000Z

**Overall: D (0.67)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.80% |  |
| Net Profit YoY | -19.28% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.11 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.60B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 244.64M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -17.56% | E |
| Profit Margin | -120.24% | E |
| Gross Margin | -21.06% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.80% | D |
| Net Profit YoY | -19.28% | D |
| Total Assets YoY | -10.04% | E |
| Net Assets YoY | -20.71% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -83.16% | D |
| OCF YoY | -2.80% | D |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.11 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 30.03% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Obio Technology (Shanghai) Corp., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-17.56%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-120.24%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-21.06%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.80%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-19.28%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.04%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-20.71%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-83.16%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-2.80%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.11",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "30.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | WuXi AppTec (SH.603259) | A | A | C | B | B | B |
| 02 | Pharmaron (SZ.300759) | B | B | C | C | B | B |
| 03 | Chemexpress (SH.688131) | B | A | C | C | B | B |
| 04 | HitGen (SH.688222) | B | B | D | B | B | B |
| 05 | Sepax Technologies (SH.688758) | C | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.64 | 20/27 | - | - | - |
| PB | 3.11 | 9/27 | 3.28 | 3.04 | 2.27 |
| PS (TTM) | 18.81 | 24/27 | 20.19 | 18.60 | 15.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-04-19T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.09 |
| Highest Target | 10.20 |
| Lowest Target | 10.20 |

## References

- [Company Overview](https://longbridge.com/en/quote/688238.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688238.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688238.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.